APA (7th ed.) Citation

JC, B., H, H., LL, H., I, F., JR, M., JJ, M., . . . AL, C. (2017). A Phase II Randomized Trial (GO27827) of First-Line FOLFOX Plus Bevacizumab with or Without the MET Inhibitor Onartuzumab in Patients with Metastatic Colorectal Cancer. The oncologist, 22(3), 264. https://doi.org/10.1634/theoncologist.2016-0223

Chicago Style (17th ed.) Citation

JC, Bendell, et al. "A Phase II Randomized Trial (GO27827) of First-Line FOLFOX Plus Bevacizumab with or Without the MET Inhibitor Onartuzumab in Patients with Metastatic Colorectal Cancer." The Oncologist 22, no. 3 (2017): 264. https://doi.org/10.1634/theoncologist.2016-0223.

MLA (9th ed.) Citation

JC, Bendell, et al. "A Phase II Randomized Trial (GO27827) of First-Line FOLFOX Plus Bevacizumab with or Without the MET Inhibitor Onartuzumab in Patients with Metastatic Colorectal Cancer." The Oncologist, vol. 22, no. 3, 2017, p. 264, https://doi.org/10.1634/theoncologist.2016-0223.